1-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)piperidine-4-carboxylic acid | 1000211-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)piperidine-4-carboxylic acid
• 英文别名: 1-(3,4-dihydro-2H-quinoline-1-carbonyl)piperidine-4-carboxylic acid
• CAS: 1000211-90-4
• 化学式: C₁₆H₂₀N₂O₃
• 分子量: 288.346
• InChiKey: WLUCTAOEBVZRSX-UHFFFAOYSA-N

物化性质

• 沸点：
  483.8±45.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  60.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)piperidine-4-carboxylic acid 在 1-羟基苯并三唑 、 2-叔丁基亚氨基-2-二乙基氨基-1,3-二甲基全氢-1,3,2-二氮杂磷 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 对甲苯磺酰氯 、 甲胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 生成 (3,4-dihydroquinolin-1(2H)-yl)(4-(4,5-dimethyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl)methanone
  参考文献：
  名称：

  Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11β-hydroxysteroid-dehydrogenase type 1

  摘要：

  A High Throughput Screening campaign allowed the identification of a novel class of ureas as 11 beta-HSD1 inhibitors. Rational chemical optimization provided potent and selective inhibitors of both human and murine 11 beta-HSD1 with an appropriate ADME profile and ex vivo activity in target tissues. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.111
• 作为产物：
  描述：

  ethyl 1-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)piperidine-4-carboxylate 在 sodium hydroxide 、 乙醇 、 水 、 盐酸 作用下， 反应 4.5h， 生成 1-(3,4-dihydroquinolin-1(2H)-ylcarbonyl)piperidine-4-carboxylic acid
  参考文献：
  名称：

  DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE

  摘要：

  本发明涉及一种具有以下式（I）的化合物： 其中i、j、n、o、p、q、r、R1a、R1b、R1c、R1d、R2a、R2b、R2c、R2d、R3a、R3b和R4如本文所定义，或其与酸的加合盐，或其水合物或溶剂合物，其制备、药物组合物以及用于治疗11β-HSD1酶参与的疾病的用途。

  公开号：

  US20090176775A1

文献信息

• DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE
  申请人：BRAUN Alain

  公开号：US20090176775A1

  公开（公告）日：2009-07-09

  The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R 1a , R 1b , R 1c , R 1d , R 2a , R 2b , R 2c , R 2d , R 3a , R 3b and R 4 are as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11β-HSD1 is involved.

  本发明涉及一种具有以下式（I）的化合物： 其中i、j、n、o、p、q、r、R1a、R1b、R1c、R1d、R2a、R2b、R2c、R2d、R3a、R3b和R4如本文所定义，或其与酸的加合盐，或其水合物或溶剂合物，其制备、药物组合物以及用于治疗11β-HSD1酶参与的疾病的用途。
• Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators
  申请人：Sanofi-Aventis

  公开号：US07947834B2

  公开（公告）日：2011-05-24

  The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R2d, R3a, R3b and R4 are as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11β-HSD1 is involved.

  本发明涉及式（I）的化合物：其中i、j、n、o、p、q、r、R1a、R1b、R1c、R1d、R2a、R2b、R2c、R2d、R3a、R3b和R4如本文所定义的，或其与酸的加成盐，或其水合物或溶剂化物，其制备方法、药物组合物以及用于治疗酶11β-HSD1参与的疾病的用途。
• Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors
  作者：Jesus M. Ontoria、Laura Llauger Bufi、Caterina Torrisi、Alberto Bresciani、Claudia Giomini、Michael Rowley、Sergio Serafini、Hu Bin、Wu Hao、Christian Steinkühler、Philip Jones

  DOI：10.1016/j.bmcl.2011.07.031

  日期：2011.9

  The Hedgehog (Hh-) signalling pathway is a key developmental pathway and there is a growing body of evidence showing that this pathway is aberrantly reactivated in a number of human tumors. Novel agents capable of inhibiting this pathway are sought, and an entirely novel series of smoothened (Smo) antagonists capable of inhibiting the pathway have been identified through uHTS screening. Extensive exploration of the scaffold identified the key functionalities necessary for potency, enabling potent nanomolar Smo antagonists like 91 and 94 to be developed. Optimization resulted in the most advanced compounds displaying low serum shift, clean off-targets profile, and moderate clearance in both rats and dogs. These compounds are valuable tools with which to probe the biology of the Hh-pathway. (C) 2011 Elsevier Ltd. All rights reserved.
• DÉRIVÉS D'URÉES DE PIPERIDINE OU PYRROLIDINE, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
  申请人：Sanofi-Aventis

  公开号：EP2044057A2

  公开（公告）日：2009-04-08
• US7947834B2
  申请人：——

  公开号：US7947834B2

  公开（公告）日：2011-05-24